Back to today’s briefing

Story perspectives

AbbVie to Acquire Psychedelic Drug for $1.2 Billion

8/25/2025

44 8

Summary

Story summary

AbbVie plans to acquire Gilgamesh Pharmaceuticals' psychedelic drug bretisilocin for up to $1.2 billion, reflecting growing interest in psychedelics for major depression treatment.
Gilgamesh will establish a new company for its employees and other drug programs.
This acquisition follows AbbVie's earlier $9 billion purchase of Cerevel Therapeutics, which encountered trial challenges.

1 of 1

Story summary

AbbVie plans to acquire Gilgamesh Pharmaceuticals' psychedelic drug bretisilocin for up to $1.2 billion, reflecting growing interest in psychedelics for major depression treatment.
Gilgamesh will establish a new company for its employees and other drug programs.
This acquisition follows AbbVie's earlier $9 billion purchase of Cerevel Therapeutics, which encountered trial challenges.